ADVERTISEMENT

Clinical Summary

Intravenous iron may benefit patients with chronic heart failure

Jenny Blair, MD   |   16 November 2022

Takeaway

  • In patients with chronic heart failure (CHF), intravenous ferric derisomaltose was associated with fewer cardiac adverse events.
  • Study missed its primary endpoint of reducing CHF admissions.
  • However, authors contend that in combination with the AFFIRM-AHF  iron-repletion trial, the weight of the evidence favours intravenous iron to reduce CHF admissions.

Why...

          

November Challenge

Ends in 1d 5h
left
right

Topic Challenges

left
right